Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Astellas collaborates with Proteostasis on UPR candidates in possible $1.2bn deal

Executive Summary

Proteostasis Therapeutics Inc. (mostly focused on orphan and neurodegenerative diseases caused by defects in protein folding, trafficking, and clearance) and Astellas Pharma Inc. will research and develop therapeutic candidates that modulate the unfolded protein response (UPR) pathway.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register